Lupin stocks are expected to open on a weak note today as the company expects the US Food and Drug Administration's combined warning letter for its formulation plants
Lupin stocks are expected to open on a weak note today as the company expects the US Food and Drug Administration's combined warning letter for its formulation plants at Goa and Pithampur to hit 25-30 potential launches till 2018-19 (Apr-Mar). However, the company has identified about a dozen products for site transfer on that account.
Both the plants together contribute more than half to the drug maker's US sales and about 20% of total sales. Some of the significantly older products that the company planned to launch were from the Goa facility, while some extended-release drugs were from Pithampur.
Watch complete news on Times Now
Comments :
Post a Comment